Mutant PIK3CA-mediated pancreatic tumorigenesis and the response to PI3K pathway inhibition.

被引：1
|
作者：
Payne, Susan
Maher, Molly
Nguyen Tran
Van DeHey, Dana
Tyler, Foley
Yeuh, Alexander
Leystra, Alyssa A.
Pasch, Cheri
Clipson, Linda
Matkowskyj, Kristina
Deming, Dustin A.
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[2] Univ Wisconsin, Dept Oncol, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15273
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
    S N Payne
    M E Maher
    N H Tran
    D R Van De Hey
    T M Foley
    A E Yueh
    A A Leystra
    C A Pasch
    J J Jeffrey
    L Clipson
    K A Matkowskyj
    D A Deming
    Oncogenesis, 2015, 4 : e169 - e169
  • [4] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
    Payne, S. N.
    Maher, M. E.
    Tran, N. H.
    Van De Hey, D. R.
    Foley, T. M.
    Yueh, A. E.
    Leystra, A. A.
    Pasch, C. A.
    Jeffrey, J. J.
    Clipson, L.
    Matkowskyj, K. A.
    Deming, D. A.
    ONCOGENESIS, 2015, 4 : e169 - e169
  • [5] MiR-592 Attenuates Tamoxifen Resistance in Breast Cancer Through PIK3CA-Mediated PI3K/AKT/mTOR Signaling Pathway
    Jin, Conghui
    Gao, Xiangxiang
    Ni, Jingyi
    Zhang, Baochun
    Wang, Zhenxin
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2024, : 2051 - 2065
  • [6] Resistance to PI3K Inhibition in Pancreatic Cancer is Mediated through the ErbB Pathway
    Tignanelli, C.
    Torphy, R. J.
    Stratford, J.
    Moffitt, R. A.
    Reuther, R.
    Loeza, S. G. Herrera
    Johnson, G. L.
    Yeh, J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S101 - S101
  • [7] Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
    Payne, Susan
    Foley, Tyler
    Pasch, Cheri
    Yueh, Alexander
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    CANCER RESEARCH, 2016, 76
  • [8] Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma
    Shi, Ruoshi
    Li, Ming
    Raghavan, Vibha
    Tam, Shirley
    Cabanero, Michael
    Pham, Nhu-An
    Shepherd, Frances A.
    Moghal, Nadeem
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2018, 24 (23) : 5990 - 6000
  • [9] Papillary Intralymphatic Angioendothelioma in a Child With PIK3CA-Related Overgrowth Spectrum: Implication of PI3K Pathway in the Vascular Tumorigenesis
    Debelenko, Larisa
    Mansukhani, Mahesh M.
    Remotti, Fabrizio
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2023, 26 (02) : 166 - 171
  • [10] Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
    Pixu Liu
    Hailing Cheng
    Stephanie Santiago
    Maria Raeder
    Fan Zhang
    Adam Isabella
    Janet Yang
    Derek J Semaan
    Changzhong Chen
    Edward A Fox
    Nathanael S Gray
    John Monahan
    Robert Schlegel
    Rameen Beroukhim
    Gordon B Mills
    Jean J Zhao
    Nature Medicine, 2011, 17 : 1116 - 1120
12345